Skip to main content
SpringerLink
Log in

Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Availability of data and material

Here we present outcome results from a recent analysis of patients registered in the Spanish guidelines for the treatment of the first relapse of acute lymphoblastic leukemia SEHOP/PETHEMA 2015.

Abbreviations

ALL:

Acute lymphoblastic leukemia

B-ALL:

B-cell precursor ALL

CR:

Complete remission

EFS:

Event free survival

HR:

High risk

HSCT:

Allogeneic hematopoietic stem cell transplantation

MoAb:

Monoclonal antibodies

MRD:

Minimal residual disease

OS:

Overall survival

R/R:

Refractory/relapsed

SEHOP:

Spanish Society of Pediatric Hematology and Oncology

References

  1. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52.

    Article  CAS  Google Scholar 

  2. Pardo Romaguera E, Muñoz López A, Valero Poveda S, Porta Cebolla S, Cañete Nieto A, Barreda Reines MS, Persis Bonet R. Cáncer infantil en España. Estadísticas 1980–2019. In: Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2020 (Edición preliminar).

  3. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14:e205–17.

    Article  Google Scholar 

  4. Eckert C, Hagedom N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance or early and late assessment. Leukemia. 2015;29(8):1648–55. https://doi.org/10.1038/leu.2015.59.

    Article  CAS  PubMed  Google Scholar 

  5. Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhoos B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128(7):911–22. https://doi.org/10.1182/blood-2016-03-704973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, et al. Outcome after first relapse in childhood acute lymphoblastic leukemia—lessons from the United Kingdom R2 trial. Br J Haemathol. 2005;130:65–75.

    Google Scholar 

  7. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrapper M, Janka-Schaub G, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol. 2005;23:7942–50.

    Article  Google Scholar 

  8. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Haws R, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group study CCG-1941. J Clin Oncol. 2006;24(19):3150–6.

    Article  Google Scholar 

  9. Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haemathol. 2009;144:559–70.

    Article  Google Scholar 

  10. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339–47.

    Article  CAS  Google Scholar 

  11. Saarinen-Pihkala UM, Heilmann C, Winiarski J, Glomstein A, Abrahamsson J, Schroeder H, et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol. 2006;24:5750–62.

    Article  Google Scholar 

  12. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinso R, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortiumstudy. J Clin Oncol. 2010;28(4):648–54.

    Article  Google Scholar 

  13. Silverman LB. Balancing cure and long-term risk in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2014;2014(1):190–7. https://doi.org/10.1182/asheducation-2014.1.190.

    Article  Google Scholar 

  14. Algeri M, Del Bufalo F, Galaverna F, Locatelli F. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Expert Rev Hematol. 2018;25:1–12.

    Google Scholar 

  15. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cellengager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40.

    Article  CAS  Google Scholar 

  16. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.

    Article  CAS  Google Scholar 

  17. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh A, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Eng J Med. 2017;376(9):836–47.

    Article  CAS  Google Scholar 

  18. von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381–9.

    Article  Google Scholar 

  19. Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77. https://doi.org/10.1038/s41408-020-00342-x.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fuster JL, Molinos-Quintana A, Fuentes C, Fernández JM, Velasco P, Pascual T, et al. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP). Br J Haematol. 2020;190(5):764–71.

  21. Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, et al. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv. 2019;3(13):1926–9.

    Article  CAS  Google Scholar 

  22. Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1498–504.

    Article  CAS  Google Scholar 

  23. Zugmaier G, Gökbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578–84.

    Article  CAS  Google Scholar 

  24. Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019;3(21):3393–405.

    Article  Google Scholar 

  25. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843–54. https://doi.org/10.1001/jama.2021.0987.

    Article  CAS  PubMed  Google Scholar 

  26. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemiaa randomized clinical trial. JAMA. 2021;325(9):833–42. https://doi.org/10.1001/jama.2021.0669.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Pediatric Oncology and Hematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Ctra. Madrid-Cartagena s/n, El Palmar, 30120, Murcia, Spain

    J. L. Fuster

  2. Pediatric Oncology, Hematology and Stem Cell Transplantation Department, Hospital Niño Jesús, Madrid, Spain

    F. Bautista

  3. Pediatric Oncology and Hematology Department, Hospital Universitario La Paz, Madrid, Spain

    B. González

  4. Pediatric Oncology and Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

    J. M. Fernández

  5. Pediatric Hematology and Oncology Department, Hospital San Joan de Déu, Institut de Recerca San Joan de Déu, Barcelona, Spain

    S. Rives & J. L. Dapena

Authors
  1. J. L. Fuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bautista
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. González
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. M. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Rives
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. L. Dapena
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)

Contributions

All authors contributed to the acquisition, analysis, and interpretation of the data, revised the manuscript critically, approved the final version for publication, and agreed to be accountable for the results presented; JLF generated first and subsequent drafts of the manuscript.

Corresponding author

Correspondence to J. L. Fuster.

Ethics declarations

Conflict of interest

JL Fuster is a consultant/advisory member for Amgen, Jazz Pharmaceuticals and Novartis, receives honoraria for speaking at symposia from Amgen, Servier, Jazz Pharmaceuticals and Pfizer and support for attending symposia from Servier and Jazz Pharmaceuticals. F Bautista is a member of a data monitoring committee (DMC) for a clinical trial sponsored by Sanofi, had a consultant or advisory role for Bayer, Amgen RocheGenentech and Eusa Pharma and received honoraria for speaking at symposia from RocheGenentech. B González has a consultant or advisory role for Servier, Amgen and Jazz Pharmaceuticlas and received support for attending symposia from Jazz Pharmaceuticals, Servier and Novartis. JM Fernández is a consultant/advisory member for Amgen, Jazz Pharmaceuticals abd Novartis, receives honoraria for speaking at symposia from Amgen, Servier, Jazz Pharmaceuticals, Gilead and Pfizer and support for attending symposia from Servier, Pfizer, Gilead and Jazz Pharmaceuticals. JL Dapena participated in advisory boards for Amgen, Servier, Jazz Pharmaceuticals and Sobi; received honoraria for speaking at symposia from Amgen, Servier, Jazz Pharmaceuticals and Sobi, as well as support for attending symposia from Servier, Gilead and Jazz Pharmaceuticals. S Rives is a member of a data monitoring committee (DMC) and from a Data Safety Monitoring Board for two clinical trials sponsored by Novartis, participated in advisory boards for Amgen, Novartis, Jazz Pharma, Baxalta/Servier, Kite, Celgene and received honoraria for speaking at symposia from Novartis, Jazz Pharma, Baxalta/Servier, as well as support for attending symposia from Novartis, Jazz Pharma, Novartis, Jazz Pharma, Baxalta/Servier and Celgene.

Ethics approval

The Spanish guidelines for the treatment of the first relapse of acute lymphoblastic leukemia SEHOP/PETHEMA 2015 was approved by the Clinical Research Ethics Committee from Clinical University Hospital “Virgen de la Arrixaca” in September 2016. All participants (legal guardians) signed informed consent.

Informed consent

All authors consent to participate and approved the content of the manuscript.

Consent for publication

All authors consent for publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fuster, J.L., Bautista, F., González, B. et al. Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia. Clin Transl Oncol 23, 1963–1966 (2021). https://doi.org/10.1007/s12094-021-02590-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02590-0

Search

Navigation